Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
Portfolio Pulse from Vandana Singh
Biogen and UCB's Phase 3 study of dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, showing improvement over placebo. A second Phase 3 trial is planned for 2024. Biogen's stock rose 1.66% in premarket trading.
September 24, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biogen's Phase 3 trial for dapirolizumab pegol in SLE met its primary endpoint, leading to a 1.66% increase in premarket stock price. A second trial is planned for 2024.
The successful Phase 3 trial results for dapirolizumab pegol, a key drug candidate for Biogen, positively impacted the stock price. The announcement of a second trial further supports potential future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90